1. Novo Nordisk is expected to deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance; 2. Despite competition and short-term manufacturing limitations, NVO maintains a strong market position in a high-growth industry; 3. The valuation model projects a $134.60 price target for December 2026, reflecting a Strong Buy with significant upside potential.